who prescribes tirzepatide What is the Tirzepatide Starting

Tirzepatide causes water loss through GI effects

Building on the therapeutic success of GLP-1RAs, recent pharmacological developments have introduced GLP-1 with glucose-dependent insulinotropic polypeptide (GIP)/glucagon (GCG) dual or triple receptor agonists simultaneously target multiple incretin pathways, offering a novel multi-targeted approach to MASLD treatment

As a result, patients naturally consume fewer calories, resulting in weight loss

Researchers are exploring whether GLP-1 medications used for diabetes and weight loss could treat Alzheimers and addiction, but public concerns persist about long-term safety

Many patients find that structured meal planning helps compensate for loss of medication-induced appetite suppression

The study completed in December 2022 and results demonstrated that OST-122 was well-tolerated with no SAEs or significant safety concerns, achieving minimal plasma concentrations (average Cmax 0.92 ng/mL on day 28) while maintaining therapeutically relevant colon tissue levels (15.5 g/g tissue), confirming the compounds gut-restricted profile ( Thanks to the positive safety signals and promising trends in clinical efficacy in this Phase 1b/2a trial, the development program for Oncostellae in UC is continuing in development as a gut-restricted JAK inhibitor approach